

Index

A

- Adequate intake (AI), 63
- Amiodarone, 82
- Amiodarone-induced hypothyroidism (AIH), 82
- Amiodarone-induced thyrotoxicosis (AIT), 82, 143

B

- Biofortification
 - bread intake, 114–116
 - of eggs, 116
 - of fish, 112–113
 - and fortification, 107
 - of meat, 116
 - of vegetables, 116–117
- Brain damage and neurocognitive impairment, 69–70

C

- Cretinism, 3, 10, 34, 69, 94, 95, 123, 125
 - clinical manifestations, 50–51
 - cognition and motor function, 51–52
 - pathogenesis, 50–51

D

- Dairy products, 110–112
- Danish iodization program
 - dietary iodine sources, 109
 - iodine fortification of bread, 114–116
 - urinary iodine excretion, 116
- Dietary reference intake, iodine, 63–64
- Diet records, 21–22, 81

- Discovery of iodine, 3–5
- Dried blood spot (DBS) thyroglobulin method, 20, 76–77

E

- Endemic goiter
 - bread iodation, 81
 - difuse goiter, 48–49
 - epidemiology, 47
 - etiology, 3, 7, 48
 - iodine insufficiency, 46
 - pathophysiology, 48–49
 - prevention, 1–2
 - prophylaxis, 4, 5, 7, 11, 92
 - and thyroid dysfunction, 68–69
- Environmental iodine uptake inhibitors
 - NIS inhibitors, 147–148
 - nitrate, 146–147
 - perchlorate, 142–145
 - thiocyanate, 145–146
- Epidemiology, iodine deficiency, 29–43
 - cognitive impairment in children, 30
 - maternal and fetal hypothyroidism, 30
 - naturally low soil iodine levels, 30, 31
 - thyroid dysfunction, 30
- Estimated average requirement (EAR), 34, 63, 64, 71, 72
- Excess iodine exposure/ingestion
 - adverse health effects, 85
 - amiodarone, 82
 - diet, 81
 - drinking water, 84
 - expectorants, 84
 - food preservatives, 84
 - iodinated contrast media, 82–83

- Excess iodine exposure/ingestion (*cont.*)
- iodine fortification, 80
 - iodine-induced hyperthyroidism, 78
 - iodine-induced hypothyroidism, 78–79
 - iodine-induced thyroid autoimmunity, 79
 - medical uses, 84
 - mouthwashes, 84
 - parenteral preparations, 84
 - population measures, 76–77
 - prescribed medications, 84
 - risk assessment models, 85
 - sources, 79, 80
 - thyroidal response, 77–78
 - topical antiseptics, 84
 - topical iodine, 83
 - TUL, 76, 77
 - vaginal douches, 84
 - vitamins and supplements, 84
- F**
- Food fortification, 80, 97, 102. *See also*
 - Non-salt food fortification programs
 - Food frequency questionnaire (FFQ), 21, 22
 - Food preservatives, 84
- H**
- Hyperthyroidism, 49, 68, 76, 79, 106
 - by Graves' disease, 107, 146
 - iodine-induced, 78
 - perchlorate, 143
 - prevalence, 80
 - radioiodine, 107
 - risk of, 82
 - by thyroid autonomy, 114, 135
 - treatment of, 84
 - Hypothyroidism
 - incidence of, 136
 - iodine-induced, 78–79, 82, 83
 - maternal, 30, 49–50
 - neurological damage, 51, 106
 - reproductive failure, 49–50
- I**
- Iodinated contrast media, 82–83
 - Iodine
 - fortification, 76, 80, 106, 107, 109, 115, 116
 - intake level and thyroid disease, 106
 - prophylaxis, 9, 49, 52, 93, 127, 135
 - Iodine biofortification, 110–112
 - Iodine deficiency
 - endemic goiter, 1–2
 - in Europe, 2–3
 - evidence-based methods, 73
 - mild-moderate deficiency
 - adverse biologic effects, 67
 - epidemiological criteria, 61, 62, 70
 - goitrogens role, 62–63
 - and iodine intake assessment, 64–65
 - severe deficiency
 - endemic cretinism, 50–52
 - endemic goiter, 46–49
 - epidemiological criteria, 46
 - goiter, 46
 - hypothyroidism, 46, 49–50
 - and iron deficiency, 52
 - population iodine nutrition status, 46
 - reproductive failure, 46
 - and vitamin A deficiency, 52–53
 - in Switzerland, 10–11
 - in United States, 6–10
 - Iodine-induced hyperthyroidism, 78
 - Iodine-induced hypothyroidism, 78–79
 - Iodine-induced thyroid autoimmunity, 79
 - Iodine nutrition
 - biomarkers, 31, 32
 - epidemiological criteria, 31, 32
 - food industry, 40
 - global databases, 32
 - global status
 - dairy farming practices, 37
 - iodine deficiency control programs, 36
 - iodine excess intake, 37
 - in pregnant women, 37–40
 - school-age children, 35–36
 - global trends, 34, 35
 - human consumption, 40
 - national iodine status, 32, 33
 - national/sub-national UIC surveys, 32
 - population-based sampling frame, 32
 - UIC analysis, 32–34
 - Iodine supplementation
 - of mild-moderate deficiency areas
 - in childhood and cognitive function, 133–134
 - gestational thyroid indices, 134
 - long term exposure before pregnancy, 134
 - maternal iodine impact (*see* (Maternal iodine supplementation))
 - for pregnancy and lactation, 123–125
 - risks of, 135–136
 - for school-aged children, 122
 - in severely deficiency regions
 - on growth and childhood cognition, 127–128

- on infant mortality, 127
 - randomized control trial, 125, 126
- L**
- Lowest observed adverse effect level (LOAEL), 85
- M**
- Maternal hypothyroidism, 49–50
 - Maternal iodine supplementation
 - infant mortality, 127
 - of mild-moderate deficiency and child neurodevelopmental function, 133
 - on maternal thyroid function, 128, 132
 - on maternal thyroid volume, 128, 132
 - on neonatal thyroid parameters, 132
 - randomized controlled trials, 129–131
 - thyroglobulin, 132
 - psychomotor test scores, 125
 - Median urinary iodine concentrations (mUIC), 31, 32, 34, 36, 39
- N**
- Nitrate
 - exposure sources, 146
 - perchlorate, 142
 - thyroid function effects, 142, 146–147
 - Non-salt food fortification programs. *See also* Biofortification
 - bread intake, 114–116
 - dairy products, 110–112
 - dietary iodine sources, 109
 - No observed adverse effect level (NOAEL), 85
- P**
- Perchlorate
 - exposure sources, 142
 - general population studies, 144
 - healthy volunteer studies, 143
 - lactation, 144–145
 - occupational studies, 143
 - pharmacologic effects, thyroid function, 143
 - pregnancy studies, 144
 - Population iodine status
 - biochemical assessment
 - thyroglobulin, 19–20
 - thyroid hormones, 19
 - TSH, 18–19
 - urinary iodine, 16–18
 - biomarkers, advantages and disadvantages, 23
 - clinical assessment, 20–21
 - dietary assessment, 21–22
 - thyroid volume, 20–21
- Pregnant women (PW)**
- daily requirement, 37
 - epidemiological criteria, 37, 38
 - iodine status classification, 38, 39
 - iodine supplementation, 39–40
 - mUIC, 38, 39
- R**
- Recommended dietary intake (RDI), 63–65, 71, 72
 - Reproductive failure, 49–50
- S**
- Salt iodization, 30
 - elimination programming, 100
 - in food industry and consumer salt, 99
 - history
 - during 1970s, 94
 - during 1980s, 94–95
 - into 1960s, 92–93
 - during 1990 to 2000, 95–97
 - international collaboration, 101–102
 - iodine content surveillance in consumer salt, 99–100
 - market monitoring, 99
 - mean (adult) population salt intakes, 98
 - national partnership, 100–101
 - population assessment, 93
 - regional/voluntary approaches, 97
 - Sodium-iodide symporter (NIS)
 - inhibitors
 - effects of, 147
 - mitigation strategies, 148
 - regulation of, 147–148
 - thiocyanate, 110
 - mammary gland lactation, 109
 - nitrate, 146
 - perchlorate, lactation, 144–145
 - thiocyanate, 145
- T**
- Thiocyanate, 48, 63, 110, 142
 - exposure sources, 145
 - thyroidal effects, 145–146
 - in tobacco, 63
 - Thyroglobulin (Tg), 16, 19–20, 24
 - Thyroidal response, 77–78

- Thyroid-stimulating hormone (TSH), 18–20,
46, 83, 124, 128, 132, 147
chronic TSH overstimulation, 48
hyperplasia, 61
lactation, 145
of newborn infants, 81
population studies, 144
pregnancy studies, 144
in vitamin A deficiency, 53
- Tolerable upper level (TUL), 76, 77
- Topical antiseptics, 83, 84
- Topical iodine, 83
- U**
- Universal salt iodization (USI), 34, 36, 38, 96,
100–102, 122–124
- Urinary iodine concentration (UIC), 16–18,
21, 22, 30, 31, 72, 83, 123, 134, 135
and iodine intake assessment, 64–65
iodine nutrition, 38
iodine status, population, 16, 17
mild iodine deficiency, 71
neurocognitive outcomes, children, 70
population iodine deficiency severity,
66–67
pregnant women, iodine intake, 17
and UIE, 66–67
- Urinary iodine excretion (UIE), 16–18, 71, 72
goiter prevalence, 67, 68
population iodine deficiency severity,
66–67
and UIC, 66–67
- V**
- Vitamin(s), 84, 92, 122
- Vitamin A deficiency (VAD), 52–53